<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37577803</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-681X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>7-8</Issue><PubDate><Year>2023</Year><Season>Oct-Nov</Season></PubDate></JournalIssue><Title>Medical decision making : an international journal of the Society for Medical Decision Making</Title><ISOAbbreviation>Med Decis Making</ISOAbbreviation></Journal><ArticleTitle>Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.</ArticleTitle><Pagination><StartPage>850</StartPage><EndPage>862</EndPage><MedlinePgn>850-862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0272989X231191127</ELocationID><Abstract><AbstractText Label="BACKGROUND">Polio antiviral drugs (PAVDs) may provide a critical tool in the eradication endgame by stopping poliovirus infections in immunodeficient individuals who may not clear the virus without therapeutic intervention. Although prolonged/chronic poliovirus excreters are rare, they represent a source of poliovirus reintroduction into the general population. Prior studies that assumed the successful cessation of all oral poliovirus vaccine (OPV) use estimated the potential upper bound of the incremental net benefits (INBs) of resource investments in research and development of PAVDs. However, delays in polio eradication, OPV cessation, and the development of PAVDs necessitate an updated economic analysis to reevaluate the costs and benefits of further investments in PAVDs.</AbstractText><AbstractText Label="METHODS">Using a global integrated model of polio transmission, immunity, vaccine dynamics, risks, and economics, we explore the risks of reintroduction of polio transmission due to immunodeficiency-related vaccine-derived poliovirus (iVDPV) excreters and reevaluate the upper bound of the INBs of PAVDs.</AbstractText><AbstractText Label="RESULTS">Under the current conditions, for which the use of OPV will likely continue for the foreseeable future, even with successful eradication of type 1 wild poliovirus by the end of 2023 and continued use of Sabin OPV for outbreak response, we estimate an upper bound INB of 60 million US$2019. With &gt;100 million US$2019 already invested in PAVD development and with the introduction of novel OPVs that are less likely to revert to neurovirulence, our analysis suggests the expected INBs of PAVDs would not offset their costs.</AbstractText><AbstractText Label="CONCLUSIONS">While PAVDs could play an important role in the polio endgame, their expected economic benefits drop with ongoing OPV use and poliovirus transmissions. However, stakeholders may pursue the development of PAVDs as a desired product regardless of their economic benefits.HighlightsWhile polio antiviral drugs could play an important role in the polio endgame, their expected economic benefits continue to drop with delays in polio eradication and the continued use of oral poliovirus vaccines.The incremental net benefits of investments in polio antiviral drug development and screening for immunodeficiency-related circulating polioviruses are small.Limited global resources are better spent on increasing global population immunity to polioviruses to stop and prevent poliovirus transmission.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Badizadegan</LastName><ForeName>Kamran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalkowska</LastName><ForeName>Dominika A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kimberly M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-0849-9147</Identifier><AffiliationInfo><Affiliation>Kid Risk, Inc., Orlando, FL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>INV-009333</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Decis Making</MedlineTA><NlmUniqueID>8109073</NlmUniqueID><ISSNLinking>0272-989X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral drugs</Keyword><Keyword MajorTopicYN="N">disease eradication</Keyword><Keyword MajorTopicYN="N">modeling</Keyword><Keyword MajorTopicYN="N">polio</Keyword><Keyword MajorTopicYN="N">prevention</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>6</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>14</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37577803</ArticleId><ArticleId IdType="mid">NIHMS1946326</ArticleId><ArticleId IdType="pmc">PMC10680042</ArticleId><ArticleId IdType="doi">10.1177/0272989X231191127</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tangye SG, Al-Herz W, Bousfiha AA, et al. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020; 40: 24–64. DOI: 10.1007/s10875-019-00737-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-019-00737-x</ArticleId><ArticleId IdType="pmc">PMC7082301</ArticleId><ArticleId IdType="pubmed">31953710</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousfiha AA, Jeddane L, Picard C, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol 2020; 40: 66–81. DOI: 10.1007/s10875-020-00758-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-020-00758-x</ArticleId><ArticleId IdType="pmc">PMC7082388</ArticleId><ArticleId IdType="pubmed">32048120</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26: 1471–1505. DOI: 10.1111/j.1539-6924.2006.00827.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2006.00827.x</ArticleId><ArticleId IdType="pubmed">17184393</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio post-certification strategy: A risk mitigation strategy for a polio-free world, https://polioeradication.org/wp-content/uploads/2018/04/polio-post-certification-strategy-20180424-2.pdf (2018, accessed
June 22 2022).</Citation></Reference><Reference><Citation>MacCallum PO. Observations on the feeding of attenuated live polioviruses (Sabin) to children with hypogammaglobulinemia. Presented at the 9th Symposium of the European Association of Poliomyelitis and Allied Diseases. Stockholm, Sweden1963.</Citation></Reference><Reference><Citation>Hara M, Saito Y, Komatsu T, et al. Antigenic analysis of polioviruses isolated from a child with agammaglobulinemia and paralytic poliomyelitis after Sabin vaccine administration. Microbiology and Immunology 1981; 25: 905–913.</Citation><ArticleIdList><ArticleId IdType="pubmed">6273701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nkowane BM, Wassilak SGF, Orenstein WA, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 1987; 267: 1335–1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">3029445</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Ivanova O, Driss N, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J Infect Dis 2014; 210 Suppl 1: S368–372. DOI: 10.1093/infdis/jiu065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu065</ArticleId><ArticleId IdType="pubmed">25316857</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, Shahmahmoodi S, Abolhassani H, et al. Vaccine-derived polioviruses and children with primary immunodeficiency, Iran, 1995–2014. Emerg Infect Dis 2016; 22: 1712–1719. DOI: 10.3201/eid2210.151071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2210.151071</ArticleId><ArticleId IdType="pmc">PMC5038407</ArticleId><ArticleId IdType="pubmed">27648512</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghamohammadi A, Abolhassani H, Kutukculer N, et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Frontiers in immunology 2017; 8: 685. 20170613. DOI: 10.3389/fimmu.2017.00685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00685</ArticleId><ArticleId IdType="pmc">PMC5468416</ArticleId><ArticleId IdType="pubmed">28952612</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty MC, Madkaikar MR, Desai M, et al. Poliovirus excretion in children with primary immunodeficiency disorders, India. Emerg Infect Dis 2017; 23: 1664–1670. DOI: 10.3201/eid2310.170724.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2310.170724</ArticleId><ArticleId IdType="pmc">PMC5621533</ArticleId><ArticleId IdType="pubmed">28930011</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, Shahmahmoodi S, Nili A, et al. Vaccine-derived poliovirus infection among patients with primary immunodeficiency and effect of patient screening on disease outcomes, Iran. Emerg Infect Dis 2019; 25: 2005–2012. DOI: 10.3201/eid2511.190540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2511.190540</ArticleId><ArticleId IdType="pmc">PMC6810208</ArticleId><ArticleId IdType="pubmed">31625840</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Liao Y, Takane M, et al. Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: An analysis of the World Health Organization registry. Frontiers in immunology 2017; 8: 1103. DOI: 10.3389/fimmu.2017.01103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01103</ArticleId><ArticleId IdType="pmc">PMC5622164</ArticleId><ArticleId IdType="pubmed">28993765</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, Diop OM, Humayun A, et al. Update on immunodeficiency-associated vaccine-derived polioviruses - Worldwide, July 2018-December 2019. MMWR 2020; 69: 913–917. DOI: 10.15585/mmwr.mm6928a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio vaccines: WHO position paper - March, 2016. Weekly Epidemiol Rec 2016; 91: 145–168.</Citation></Reference><Reference><Citation>Kew OM, Sutter RW, de Gourville EM, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 2005; 59: 587–635. DOI: 10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew OM, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002; 296: 356–359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 2013; 33: 680–702. 20130307. DOI: 10.1111/risa.12022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12022</ArticleId><ArticleId IdType="pmc">PMC7890645</ArticleId><ArticleId IdType="pubmed">23470192</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA and Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. BMC Infect Dis 2015; 15: 379. 20150917. DOI: 10.1186/s12879-015-1115-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1115-5</ArticleId><ArticleId IdType="pmc">PMC4574619</ArticleId><ArticleId IdType="pubmed">26382043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA and Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters. Epidemiol Infect 2019; 147: e295. 20191024. DOI: 10.1017/S095026881900181X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S095026881900181X</ArticleId><ArticleId IdType="pmc">PMC6813650</ArticleId><ArticleId IdType="pubmed">31647050</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JP Jr, Ehresmann K, Seward J, et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis 2009; 199: 391–397.</Citation><ArticleIdList><ArticleId IdType="pubmed">19090774</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider CJ, Boualam L, Tallis G, et al. Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019–2021. Vaccine 2023; 41 Suppl 1: A58–a69. 2022/03/27. DOI: 10.1016/j.vaccine.2022.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.022</ArticleId><ArticleId IdType="pmc">PMC10546869</ArticleId><ArticleId IdType="pubmed">35337673</ArticleId></ArticleIdList></Reference><Reference><Citation>Weil M, Rahav G, Somech R, et al. First report of a persistent oropharyngeal infection of type 2 vaccine-derived poliovirus (iVDPV2) in a primary immune deficient (PID) patient after eradication of wild type 2 poliovirus. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2019; 83: 40–43. 2019/04/07. DOI: 10.1016/j.ijid.2019.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2019.03.037</ArticleId><ArticleId IdType="pubmed">30953828</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Novel oral polio vaccine type 2 (nOPV2) granted EUL recommendation, https://polioeradication.org/news-post/novel-oral-polio-vaccine-type-2-nopv2-granted-interim-emergency-use-listing-recommendation/ (2020, accessed
Nov 15 2020).</Citation></Reference><Reference><Citation>Macklin GR, Peak C, Eisenhawer M, et al. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine 2023; 41 Suppl 1: A122–A127. 20220317. DOI: 10.1016/j.vaccine.2022.02.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. GPEI Statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo. 2023. Geneva, Switzerland: World Health Organization - Global Polio Eradication Initiative.</Citation></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines 2020; 5: 26. 2020/03/29. DOI: 10.1038/s41541-020-0176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0176-7</ArticleId><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1), WHO, Geneva, 19–24
May
2008, http://apps.who.int/gb/ebwha/pdf_files/WHA61-REC1/A61_Rec1-part2-en.pdf (2008, accessed
Jun 4 2019).</Citation></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Cochi SL, et al. An economic analysis of poliovirus risk management policy options for 2013–2052. BMC Infect Dis 2015; 15: 389. 20150924. DOI: 10.1186/s12879-015-1112-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1112-8</ArticleId><ArticleId IdType="pmc">PMC4582932</ArticleId><ArticleId IdType="pubmed">26404632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, et al. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - Worldwide, 2016. MMWR 2016; 65: 934–938. DOI: 10.15585/mmwr.mm6535a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6535a3</ArticleId><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Cochi SL, et al. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal 2021; 41: 320–328. DOI: 10.1111/risa.13555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13555</ArticleId><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wilkinson A, et al. Updated characterization of poliovirus outbreak response strategies for 2019–2029: Impacts of the use of novel OPV2 strains. Risk Anal 2021; 41: 329–348. DOI: 10.1111/risa.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13622</ArticleId><ArticleId IdType="pmc">PMC7887065</ArticleId><ArticleId IdType="pubmed">33174263</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM. Polio eradication: what kind of world do we want? Lancet Infect Dis 2022; 22: 161–163. 2021/10/15. DOI: 10.1016/s1473-3099(21)00458-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(21)00458-8</ArticleId><ArticleId IdType="pmc">PMC8504921</ArticleId><ArticleId IdType="pubmed">34648732</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, O’Reilly KM, Grassly NC, et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science 2020; 368: 401–405. DOI: 10.1126/science.aba1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aba1238</ArticleId><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: Delivering on a promise, https://polioeradication.org/wp-content/uploads/2021/06/polio-eradication-strategy-2022-2026-pre-publication-version-20210609.pdf (2021, accessed
Jun 11 2021).</Citation></Reference><Reference><Citation>World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2022: conclusions and recommendations. Weekly Epidemiological Record 2022; 97: 274–275.</Citation></Reference><Reference><Citation>Kalkowska DA, Wassalik SGF, Wiesen E, et al. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. Risk Anal 2023; (in press). DOI: 10.1111/risa.14158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.14158</ArticleId><ArticleId IdType="pmc">PMC10733544</ArticleId><ArticleId IdType="pubmed">37344934</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA. An updated economic analysis of the Global Polio Eradication Initiative. Risk Anal 2021; 41: 393–406. DOI: 10.1111/risa.13665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13665</ArticleId><ArticleId IdType="pmc">PMC7894996</ArticleId><ArticleId IdType="pubmed">33590521</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA and Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. Gates Open Res 2022; 6: 5. 20220203. DOI: 10.12688/gatesopenres.13524.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/gatesopenres.13524.1</ArticleId><ArticleId IdType="pmc">PMC8881365</ArticleId><ArticleId IdType="pubmed">35280345</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA. Review of poliovirus modeling performed from 2000–2019 to support global polio eradication. Expert Rev Vaccines 2020; 19: 661–686. DOI: 10.1080/14760584.2020.1791093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2020.1791093</ArticleId><ArticleId IdType="pmc">PMC7497282</ArticleId><ArticleId IdType="pubmed">32741232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA and Thompson KM. Health and economic outcomes associated with polio vaccine policy options: 2019–2029. Risk Anal 2021; 41: 364–375. DOI: 10.1111/risa.13664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13664</ArticleId><ArticleId IdType="pmc">PMC7895457</ArticleId><ArticleId IdType="pubmed">33590519</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA and Badizadegan K. No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the editor by Chumakov et al.]. Risk Anal 2021; 41: 389–392. DOI: 10.1111/risa.13671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13671</ArticleId><ArticleId IdType="pmc">PMC8014295</ArticleId><ArticleId IdType="pubmed">33590518</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. Epidemiol Infect 2017; 145: 217–226. 20161020. DOI: 10.1017/S0950268816002302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268816002302</ArticleId><ArticleId IdType="pmc">PMC5197684</ArticleId><ArticleId IdType="pubmed">27760579</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma AM, Pürstinger G, Wimmer E, et al. Potential use of antiviral agents in polio eradication. Emerg Infect Dis 2008; 14: 545–551. DOI: 10.3201/eid1404.070439.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1404.070439</ArticleId><ArticleId IdType="pmc">PMC2570929</ArticleId><ArticleId IdType="pubmed">18394270</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay MA, Collett MS, Hincks JM, et al. Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication. J Infect Dis 2014; 210: S447–453.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316866</ArticleId></ArticleIdList></Reference><Reference><Citation>Collett MS, Hincks JR, Benschop K, et al. Antiviral activity of pocapavir in a randomized, blinded, placebo-controlled human oral poliovirus vaccine challenge model. J Infect Dis 2017; 215: 335–343. DOI: 10.1093/infdis/jiw542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw542</ArticleId><ArticleId IdType="pmc">PMC5393058</ArticleId><ArticleId IdType="pubmed">27932608</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. System Dyn Rev 2018; 34: 78–120. DOI: doi:10.1002/sdr.1589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sdr.1589</ArticleId><ArticleId IdType="pmc">PMC8455164</ArticleId><ArticleId IdType="pubmed">34552305</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA. Potential future use, costs, and value of poliovirus vaccines. Risk Anal 2021; 41: 349–363. 2020/07/10. DOI: 10.1111/risa.13557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13557</ArticleId><ArticleId IdType="pmc">PMC7984393</ArticleId><ArticleId IdType="pubmed">32645244</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, et al. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. Risk Anal 2013; 33: 703–749. 20130322. DOI: 10.1111/risa.12044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.12044</ArticleId><ArticleId IdType="pubmed">23521018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wassilak SGF, Cochi SL, et al. Global transmission of live polioviruses: Updated integrated dynamic modeling of the polio endgame. Risk Anal 2021; 41: 248–265. 2020/01/22. DOI: 10.1111/risa.13447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13447</ArticleId><ArticleId IdType="pmc">PMC7787008</ArticleId><ArticleId IdType="pubmed">31960533</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus, https://polioeradication.org/wp-content/uploads/2022/09/weekly-polio-analyses-cVDPV-20220906.pdf (2022, accessed
9 Sep 2022).</Citation></Reference><Reference><Citation>Thompson KM, Kalkowska DA and Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. Front Public Health 2023; 11: 1098419. 20230324. DOI: 10.3389/fpubh.2023.1098419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1098419</ArticleId><ArticleId IdType="pmc">PMC10080024</ArticleId><ArticleId IdType="pubmed">37033033</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM, Kalkowska DA and Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication. Expert Rev Vaccines 2021; 20: 449–460. 2021/02/19. DOI: 10.1080/14760584.2021.1891889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1891889</ArticleId><ArticleId IdType="pubmed">33599178</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. Risk Anal 2008; 28: 855–876. 2008/07/17. DOI: 10.1111/j.1539-6924.2008.01078.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1539-6924.2008.01078.x</ArticleId><ArticleId IdType="pubmed">18627544</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ and Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management J Vaccines Vaccin 2016; 7: 1000339. DOI: 10.4172/2157-7560.1000339.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000339</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM and Kalkowska DA. Reflections on modeling poliovirus transmission and the polio eradication endgame. Risk Anal 2021; 41: 229–247. 2020/04/28. DOI: 10.1111/risa.13484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13484</ArticleId><ArticleId IdType="pmc">PMC7983882</ArticleId><ArticleId IdType="pubmed">32339327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Wiesen E, Wassalik SGF, et al. Worst-case scenarios: Modeling uncontrolled type 2 polio transmission. Risk Anal 2023; (in press). DOI: 10.1111/risa.14159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.14159</ArticleId><ArticleId IdType="pmc">PMC10733542</ArticleId><ArticleId IdType="pubmed">37344376</ArticleId></ArticleIdList></Reference><Reference><Citation>Duintjer Tebbens RJ, Hampton LM, Wassilak SGF, et al. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. J Vaccines Vaccination 2016; 7: 340. DOI: 10.4172/2157-7560.1000340.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2157-7560.1000340</ArticleId><ArticleId IdType="pmc">PMC5497833</ArticleId><ArticleId IdType="pubmed">28690915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA and Thompson KM. Expected implications of globally-coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV. Risk Anal 2021; 41: 312–319. DOI: 10.1111/risa.13590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/risa.13590</ArticleId><ArticleId IdType="pmc">PMC7887090</ArticleId><ArticleId IdType="pubmed">32936466</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson KM. Polio endgame complexity: updating expectations for nOPV2. Lancet Infect Dis 2023. DOI: 10.1016/S1473-3099(23)00133-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00133-0</ArticleId><ArticleId IdType="pubmed">37178705</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Pallansch MA, Wassilak SGF, et al. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response Vaccine 2023; 41 Suppl 1: A136–A141. 2021/05/18. DOI: 10.1016/j.vaccine.2021.04.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.04.061</ArticleId><ArticleId IdType="pmc">PMC11027208</ArticleId><ArticleId IdType="pubmed">33994237</ArticleId></ArticleIdList></Reference><Reference><Citation>Anasir MI, Zarif F and Poh CL. Antivirals blocking entry of enteroviruses and therapeutic potential. J Biomed Sci 2021; 28: 10. 20210115. DOI: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermingham WH, Canning B, Wilton T, et al. Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. Frontiers in immunology 2023; 14: 1135834. 20230303. DOI: 10.3389/fimmu.2023.1135834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1135834</ArticleId><ArticleId IdType="pmc">PMC10022663</ArticleId><ArticleId IdType="pubmed">36936936</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska DA, Badizadegan K and Thompson KM. Outbreak management strategies for cocirculation of multiple poliovirus types. Vaccine 2023; 41: 3718–3727. 2023/05/01. DOI: 10.1016/j.vaccine.2023.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.04.037</ArticleId><ArticleId IdType="pubmed">37121801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>